This Will be a Randomized Comparison of the Proteomic Effects of Vicadrostat/Empagliflozin Versus Empagliflozin and Versus Empagliflozin/Spironolactone in Heart Failure Patients With Preserved Ejection Fraction
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.
Also called NCT07857772
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 200 participants
- Registry
-
NCT07857772
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07857772. Randomized; quadruple masking; primary purpose treatment. Start 2027-03 (anticipated); primary completion 2028-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- This Will be a Randomized Comparison of the Proteomic Effects of Vicadrostat/Empagliflozin Versus Empagliflozin and Versus Empagliflozin/Spironolactone in Heart Failure Patients With Preserved Ejection Fraction
- Acronym
- SPECTRA-HFpEF
- Condition
- Heart Failure With Preserved Ejection Fraction (HFPEF)
- Intervention (Drug)
- empa plus vica
- Intervention (Drug)
- Comparator: empa 10 plus spironolactone
- Lead sponsor
- Baim Institute for Clinical Research
Record details
- Record id
cardio:ct-nct07857772- Content hash
f58aa3fc57a28d1185af7237c95d7bb1a809dad228eaeb7516eb93a462ac4166